

## Executive Summary

Talus Bio discovers and develops small molecule therapeutics for previously undruggable transcription factors (TFs). TFs are the master regulators of our genome – switching genes on and off at the correct time in the correct cells. Errors in TF activity are pervasive across disease, notably oncology, fibrosis, immunology, neurology, and cardiometabolic disease.

Technology	Programs	Team
Talus Bio built a propriety technology platform called MARMOT by combining next-gen proteomics, automated biology, and AI to discover and optimize TF drugs in live, unmodified human cells.	Talus Bio's program is a first-in-class inhibitor for the Brachyury transcription factor. Brachyury is the sole driver of chordoma, a rare sarcoma with no effective treatment options. Future indication expansion opportunities exist in non-small cell lung cancer and triple-negative breast cancer.	Talus Bio is a team of world leaders at the forefront of proteomics, machine learning, and chemical biology. Talus Bio's founders trained at Harvard, UW, and Penn, and the Scientific Advisory Board includes pioneers in TF drug discovery, next-gen proteomics, and undruggable targets.


## Today

Over 200 validated TF targets linked to cancer are considered undruggable. Talus Bio is focused on:


- [1] discovery of new small molecule inhibitors for previously undrugged transcription factors, and
- [2] development of newly discovered inhibitors into first-in-class therapeutic candidates.

During 2023, **Talus Bio deployed its platform to discover new hits for 25% of all previously undruggable TFs linked to cancer.** We deeply validated 6 commercially valuable TF inhibitors for further development.

From those validated hits, we progressed a Brachyury inhibitor from hit to lead with ***in vivo* activity in 6 months** using the MARMOT platform.



## The Future



### Data drives discovery at Talus

We have amassed the first scalable data source for TF drug discovery. Our internal data meets the highest quality standards and is growing rapidly, making it ideal for training state-of-the-art AI models for drug discovery. **Our models can predict new chemistry to target undruggable transcription factors** and accelerate both the discovery of new molecules as well as the optimization of molecules towards proper drug candidates.

### Drugs for all TFs

The transcription factor space is a true blue ocean opportunity, and Talus will not be able to progress all valuable molecules on our own.

With our large library of newly discovered TF modulators, **Talus Bio is seeking pharma and biotech partners** with disease-area expertise to develop additional programs beyond our internal pipeline collaboratively.